Yüksel Ürün· @DrYukselUrun · X·· 14 小时前评分70
正文 · 原文
A milestone for personalized cancer vaccines.
INTErpath-001: 42% lower recurrence/death risk; 24-month RFS 82.2% vs 70%.
Can we extend this benefit to other cancers?
@myESMO @OncoAlert @OpenMedicineHQ #ESMO26
83 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA1按 Presidential Symposium I 对上
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.org来源：Yüksel Ürün · x.com